Published in Peptides on August 04, 2014
Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis. Molecules (2015) 0.92
Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis. Sci Rep (2016) 0.84
Secondary structure propensity and chirality of the amyloidophilic peptide p5 and its analogues impacts ligand binding - In vitro characterization. Biochem Biophys Rep (2016) 0.78
Specific Amyloid Binding of Polybasic Peptides In Vivo Is Retained by β-Sheet Conformers but Lost in the Disrupted Coil and All D-Amino Acid Variants. Mol Imaging Biol (2017) 0.76
The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice. Amyloid (2015) 0.75
Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate. J Control Release (2016) 0.75
A Peptide-Fc Opsonin with Pan-Amyloid Reactivity. Front Immunol (2017) 0.75
I-TASSER server for protein 3D structure prediction. BMC Bioinformatics (2008) 18.28
Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Amyloidosis. Annu Rev Med (2006) 3.27
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood (2010) 1.76
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology (2011) 1.59
Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta (2005) 1.58
Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch (2002) 1.48
Endocytic receptors in the renal proximal tubule. Physiology (Bethesda) (2012) 1.43
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet (1991) 1.42
In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci U S A (2011) 1.38
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A (1994) 1.35
Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging (2012) 1.33
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med (2006) 1.32
First experience with clinical-grade ([18F]FPP(RGD₂): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol (2012) 1.26
Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med (1995) 1.24
Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Mol Imaging Biol (2012) 1.13
Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis. Amyloid (2005) 1.13
Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens (2002) 1.12
In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med (2012) 1.09
A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo. PLoS One (2013) 1.02
Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med (1998) 0.98
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging (2004) 0.98
Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med (2006) 0.97
Labeling strategies of peptides with ¹⁸F for positron emission tomography. Curr Top Med Chem (2010) 0.96
Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochem J (1991) 0.95
Importance of the spatial display of charged residues in heparin-peptide interactions. Biopolymers (2010) 0.94
Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug Chem (1997) 0.90
Diagnosis and monitoring of amyloidosis. Baillieres Clin Rheumatol (1994) 0.90
Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts. Biochem Biophys Res Commun (2013) 0.88
Bioenergetic impact of tissue-specific regulation of iodothyronine deiodinases during nutritional imbalance. J Bioenerg Biomembr (2011) 0.88
Binding of a de novo designed peptide to specific glycosaminoglycans. FEBS Lett (2000) 0.87
A novel method for quantifying peripheral tissue amyloid load by using the radiolabeled amyloidophilic peptide, p5. Amyloid (2013) 0.86
Localization of type I iodothyronine 5'-deiodinase to the basolateral plasma membrane in renal cortical epithelial cells. J Biol Chem (1991) 0.83
Imaging techniques in the diagnosis of dialysis-related amyloidosis. Semin Dial (2001) 0.83
Functional transformation of gastric parietal cells and intracellular trafficking of ion channels/transporters in the apical canalicular membrane associated with acid secretion. Biol Pharm Bull (2011) 0.80
Microfluidics for synthesis of peptide-based PET tracers. Biomed Res Int (2013) 0.77